Rectal neoplasm, commonly known as rectal cancer, is a disease where cancerous cells develop in the rectum, the final section of the large intestine. Treatment approaches depend heavily on the stage and location of the cancer, ranging from surgical removal to advanced therapies combining medication and radiation. Understanding your treatment options can help you navigate this challenging journey with greater confidence.

When Cancer Strikes the Rectum: Understanding Your Treatment Journey

The main goal when treating rectal cancer is to remove the cancerous tissue, prevent the disease from spreading, and maintain as much normal bowel and bladder function as possible. Treatment decisions are highly personalized, taking into account the cancer’s stage—meaning how advanced it is—and its exact location in the rectum. Some tumors are very small and located near the surface, while others may have grown deeper into the rectal wall or spread to nearby lymph nodes or distant organs.^[1][2]

Healthcare professionals from multiple specialties work together to create treatment plans. This team typically includes surgeons, medical oncologists who specialize in cancer-treating drugs, radiation oncologists who use high-energy rays to destroy cancer cells, and pathologists who examine tissue samples under microscopes. Your personal situation, overall health, and preferences also play a crucial role in shaping your treatment plan.^[3][4]

There are treatments that medical societies around the world have approved and recommend based on decades of research. These are called standard treatments. At the same time, researchers are constantly testing new and experimental therapies in clinical trials to find better ways to fight rectal cancer. These trials may offer access to cutting-edge treatments not yet widely available.^[10][11]

Standard Treatment Approaches for Rectal Cancer

The backbone of rectal cancer treatment is surgery, particularly a technique called total mesorectal excision, or TME. This surgical method involves carefully removing the tumor along with surrounding tissue called the mesorectum, which contains blood vessels and lymph nodes. Surgeons perform this procedure under direct vision using sharp instruments to ensure clean margins around the cancer. TME has become the gold standard because it significantly reduces the chance of cancer returning in the pelvis.^[4][13]

The specific type of surgery depends on how large the tumor is and where exactly it sits in the rectum. For very small, early-stage cancers that haven’t spread beyond the inner lining, a doctor might perform a local excision. This means removing the tumor through the anus without making any cuts in the abdomen. It’s a less invasive option with quicker recovery, but it doesn’t remove lymph nodes, so it’s only suitable for certain patients.^[11][15]

For larger or more advanced tumors, surgeons perform more extensive operations. A low anterior resection removes the part of the rectum containing the cancer and then reconnects the remaining colon to what’s left of the rectum or the anus. This procedure aims to preserve the anal sphincter muscles that control bowel movements. However, when the tumor is very close to the anus or involves the sphincter muscles directly, surgeons may need to perform an abdominoperineal resection. This operation removes the rectum, anus, and part of the colon, and requires a permanent colostomy—a surgical opening in the abdomen where stool exits into a bag.^[8][15]

Many patients with rectal cancer receive treatment before surgery to shrink the tumor. This is called neoadjuvant therapy and typically combines chemotherapy and radiation given together, known as chemoradiotherapy. Chemotherapy uses drugs to kill cancer cells throughout the body, while radiation therapy uses high-energy beams to destroy cancer cells in a specific area. Common chemotherapy drugs used for rectal cancer include fluorouracil (also called 5-FU), capecitabine (an oral medication that the body converts to 5-FU), oxaliplatin, and irinotecan.^[11][12][16]

The purpose of giving these treatments before surgery is multiple. They can make large tumors smaller and easier to remove, potentially allowing surgeons to preserve the anal sphincter when they might not have been able to otherwise. Pre-operative treatment may also kill microscopic cancer cells that have spread locally but aren’t visible on scans. Radiation is typically given five days a week for five to six weeks, though a shorter schedule called short-course radiation delivers higher doses over just five days. Chemotherapy may be given simultaneously or in cycles before and after surgery.^[12][13][19]

After surgery, some patients receive additional treatment called adjuvant therapy. This typically consists of more chemotherapy cycles to eliminate any remaining cancer cells that might have escaped during surgery. The decision to give adjuvant therapy depends on the pathology results from the removed tumor—specifically, how deeply the cancer invaded the rectal wall and whether cancer was found in lymph nodes.^[12][17]

Treatment duration varies considerably. Surgery itself may last several hours, with hospital stays ranging from a few days to a week or more depending on the procedure type and any complications. Radiation therapy typically spans five to six weeks when given in standard doses. Chemotherapy may continue for several months, often six months total when combining pre- and post-operative treatment. The entire treatment journey from diagnosis through completion of all therapies can take a year or more.^[12][16]

Side effects are an unavoidable reality of rectal cancer treatment. Surgery can cause pain, infection, bleeding, and changes in bowel function. Some patients experience frequent bowel movements, urgency, or difficulty controlling gas and stool, especially after sphincter-sparing procedures. Radiation to the pelvis can cause diarrhea, rectal irritation, bladder problems, sexual dysfunction, and fatigue. Chemotherapy side effects depend on the specific drugs but commonly include nausea, vomiting, fatigue, increased infection risk due to low blood counts, numbness or tingling in hands and feet (called peripheral neuropathy), and hair thinning or loss.^[11][12]

Emerging Therapies Being Tested in Clinical Trials

Clinical trials are research studies that test whether new treatments are safe and effective. For rectal cancer, many exciting developments are currently being investigated. One major area of research involves a strategy called total neoadjuvant therapy, or TNT. Instead of giving chemotherapy both before and after surgery, TNT delivers all the chemotherapy and radiation before surgery. This approach may work better because cancer cells haven’t been disturbed by surgery and blood flow to the tumor is still intact, potentially allowing better drug delivery.^[13][14]

Several studies have shown that total neoadjuvant therapy leads to better tumor shrinkage and may allow more patients to avoid surgery altogether in select cases. Researchers are conducting Phase II and Phase III trials comparing different TNT schedules to determine which sequence of treatments works best. Phase II trials focus on determining whether a treatment shows promise and what dose to use, while Phase III trials compare the new approach directly against standard treatment in large numbers of patients.^[13][14]

Another revolutionary development is the possibility of organ preservation—meaning avoiding surgery entirely. When patients respond extremely well to neoadjuvant therapy, sometimes the tumor disappears completely or nearly so. In carefully selected cases, doctors may monitor these patients closely with frequent examinations and imaging instead of proceeding to surgery. This approach, called “watch and wait,” spares patients from surgical risks and permanent colostomies. However, it requires rigorous follow-up because there’s always a risk the cancer could return.^[13][14]

Immunotherapy represents one of the most exciting frontiers in cancer treatment. These drugs work by helping your own immune system recognize and attack cancer cells. Immunotherapy drugs called checkpoint inhibitors, including medications that block proteins called PD-1 or PD-L1, have shown remarkable results in some rectal cancer patients. However, they work primarily in patients whose tumors have a specific genetic characteristic called microsatellite instability or mismatch repair deficiency. This is found in approximately 5 to 13 percent of rectal cancer cases.^[4][14]

Clinical trials are testing checkpoint inhibitors both alone and in combination with chemotherapy. Some studies have reported cases where tumors disappeared completely with immunotherapy, allowing patients to avoid surgery altogether. These trials are being conducted at major cancer centers in the United States, Europe, and other regions worldwide. Eligibility typically requires that patients have tumors with the specific genetic markers that predict response.^[14]

Targeted therapy drugs are designed to attack specific molecules or pathways that cancer cells use to grow and survive. For rectal cancer, several targeted drugs are used, particularly for advanced disease that has spread to other organs. Bevacizumab is a drug that blocks a protein called VEGF, which tumors use to grow new blood vessels. By cutting off the tumor’s blood supply, bevacizumab can slow cancer growth. It’s often combined with chemotherapy in treatment of metastatic rectal cancer.^[12][14]

Other targeted drugs include cetuximab and panitumumab, which block a protein called EGFR on the surface of cancer cells. However, these drugs only work in patients whose tumors don’t have mutations in genes called KRAS, NRAS, or BRAF. Before starting these medications, doctors perform genetic testing on tumor samples to determine whether they’re likely to be effective. This is an example of precision medicine—tailoring treatment based on the specific genetic characteristics of each person’s cancer.^[12][14]

Researchers are also exploring shorter radiation schedules and more selective use of radiation therapy. Short-course radiation therapy delivers higher doses over just one week, compared to the traditional five to six weeks. Studies are comparing outcomes and side effects between these two approaches in Phase III trials. Some research is investigating whether certain patients with very favorable tumor characteristics might safely skip radiation altogether, potentially avoiding its long-term side effects on bowel, bladder, and sexual function.^[13][19]

Minimally invasive surgical techniques are continuously being refined. Surgeons are increasingly using laparoscopic surgery (using small incisions and a camera) or robotic-assisted surgery to remove rectal tumors. These approaches may result in less pain, faster recovery, and shorter hospital stays compared to traditional open surgery with large incisions. Clinical trials are comparing outcomes between different surgical techniques to determine which provides the best cancer control with the fewest complications.^[13][15]

Another surgical innovation being studied is transanal endoscopic microsurgery and related techniques. These approaches allow surgeons to remove early-stage rectal tumors through the anus using specialized instruments and cameras, avoiding abdominal incisions entirely. They’re particularly valuable for small tumors in the lower rectum. Studies are evaluating long-term outcomes and determining which patients are best suited for these organ-preserving procedures.^[15][19]

Clinical trials for rectal cancer are being conducted at major medical centers throughout the United States, Europe, and increasingly in other parts of the world. To be eligible for a trial, patients typically need to meet specific criteria regarding cancer stage, prior treatments, overall health status, and sometimes genetic characteristics of their tumor. Trial participation is voluntary, and patients can withdraw at any time. Your oncologist can help you search for appropriate trials and discuss whether participation might be right for you.^[3][14]

Most Common Treatment Methods

• Surgery
  • Total mesorectal excision (TME) – careful removal of tumor with surrounding tissue and lymph nodes
  • Local excision – removal of small early-stage tumors through the anus without abdominal incisions
  • Low anterior resection – removal of cancerous portion of rectum with reconnection to remaining bowel, preserving anal function
  • Abdominoperineal resection – removal of rectum and anus with creation of permanent colostomy for tumors very close to or involving the anus
  • Minimally invasive approaches – laparoscopic or robotic-assisted surgery using small incisions
  • Transanal endoscopic procedures – specialized techniques to remove tumors through the anus
• Chemotherapy
  • Fluorouracil (5-FU) – intravenous drug that interferes with cancer cell DNA production
  • Capecitabine – oral medication converted to 5-FU in the body, offering more convenient administration
  • Oxaliplatin – platinum-based drug that damages cancer cell DNA, often combined with fluorouracil
  • Irinotecan – drug that blocks enzymes cancer cells need to divide and grow
  • Combination regimens – multiple chemotherapy drugs given together for enhanced effect
• Radiation Therapy
  • Standard course radiation – treatment given five days per week for five to six weeks
  • Short-course radiation – higher doses delivered over just five days before surgery
  • Targeted radiation – carefully directed beams to minimize damage to surrounding healthy tissue
• Chemoradiotherapy
  • Neoadjuvant chemoradiotherapy – chemotherapy and radiation given together before surgery to shrink tumors
  • Total neoadjuvant therapy (TNT) – all chemotherapy and radiation delivered before surgery rather than split between before and after
  • Concurrent treatment – chemotherapy drugs given during radiation therapy to enhance radiation effectiveness
• Targeted Therapy
  • Bevacizumab – blocks VEGF protein to prevent tumor blood vessel growth
  • Cetuximab and panitumumab – block EGFR protein on cancer cells in patients without KRAS, NRAS, or BRAF mutations
  • Precision medicine approaches – treatment selected based on specific genetic characteristics of individual tumors
• Immunotherapy
  • Checkpoint inhibitors – drugs that block PD-1 or PD-L1 proteins, helping the immune system attack cancer
  • Treatment for microsatellite instability-high tumors – immunotherapy for cancers with specific genetic characteristics
  • Clinical trial combinations – immunotherapy being tested alone and with chemotherapy in research studies
• Organ Preservation Strategies
  • Watch and wait approach – close monitoring without immediate surgery for patients with complete or near-complete response to neoadjuvant therapy
  • Intensive surveillance programs – frequent examinations and imaging to detect any cancer recurrence early